Back to Agenda
Session 5: Multi-Company, Adaptive Platform Trials, and Integrated Research Platforms: Clinical Research of the Future
Session Chair(s)
Daniel Millar, MBA
Senior Director, Strategic Business Transformation
Johnson & Johnson, United States
Scott Berry, PhD
President and Senior Statistical Scientist
Berry Consultants LLC, United States
Master protocols offer substantial opportunities to achieve efficiencies in clinical development both operationally and inferentially. Maximizing these benefits and delivering on the promise of patient-centric R&D, requires going beyond the capability of any one company or organization to ensure patients have the best opportunity to participate in a trial that may benefit them and promising therapies or futile endeavors can be identified quickly, allowing reallocation of scare resources to a more fruitful direction. This section will provide updates on a multi-company, public-private partnership, adaptive platform trial, IMI EPAD (European Prevention of Alzheimer's Dementia Consortium), including learnings related to trial design, stakeholder collaboration, and the business model for sustainability.
Learning Objective : At the conclusion of this session, participants should be able to:- Understand the benefits, challenges, and critical success factors for designing and implementing multi-company platform trials
- Identify relevant case studies of prior work and opportunities on the horizon
- Identify the stakeholder landscape and how diverse stakeholder
Speaker(s)
Speaker
Kristy Draper, PhD
The University of Edinburgh, United Kingdom
Global Trial Lead for European Prevention of Alzheimer's Dementia Consortium
Speaker
Saira Ramasastry, MS, MSc
Life Sciences Advisory, United States
Partner
Overview of IMI EU-PEARL
Esther Arevalo, MS, MSc
Vall d'Hebron Institute of Research (VHIR), Spain
EU-PEARL Project Management Strategy Unit
Have an account?